AI Magazine Issue 3 2018

8 Acquisition International - Issue 3 2018 Boasting an excellent reputation and an impressive track record, Pasquale explains the firm’s attributes and standing within the market, explaining what makes the company a leader. “Local anaesthesia and pain relief are two areas in which we have been the market leader for many years in Switzerland. Moreover, we are also seeking to develop a leadership position in the growing field of neuromodulation.” Pleasing clients and exceeding their expectations on a global basis, the firmhas submitted over 350 product registrations in over 100 different countries, via the network of partners it has built over the previous five years. The first phase of expansion covered most of North, Central and South America, South East Asia, and the Pacific. Many of these registrations have yet to come through, but so far, has seen strong growth in the US, and some good returns in the Pacific. Year on Year, the company’s growth is exceeding 200%, consolidating the impressive growth stream of the last years. When discussing what differentiates Sintetica from competitors, marking them out as the best possible option for their partners, Pasquale reflects on how the culture of Sintetica and all the strategic choices are firmly based on respect. “Respect is the core value of the company, and it permeates across every employee. The concept of respect is divided into three well-defined directions. It is expressed in relation to its employees, enhancing the different characteristics of each one. Whether for work or as an individual, we aim to let people participate in activities which create a pleasant environment in which to work and express themselves. “This same concept is also expressed towards the patients using Sintetica drugs worldwide, providing them with the highest quality products and investing in innovation to imagine the best care solutions for the future. Consequently, it materialises towards its global partners, showing them loyalty, absolute ethics and both operational and development support of advanced go to market strategies.” Essentially, the values of the company and the identity that is formed through the working culture are major aspects of what differentiates the firm from others, as Pasquale alludes to. He points out that the drugs supplied by Sintetica are of Sintetica ideology, and are therefore individual in their production. “The convergence of these three well-defined areas make up the Sintetica Value Proposition. It is a distinctive and strategic element of their own identity in the wide world panorama of the pharmaceutical industry. Therefore, Sintetica does not only export drugs of the highest quality throughout the world, but also the complex of their own values. “The latter, shared by its network of global business partners, gives the global division its unique characteristics in their approach to international markets and profound value in the go to market philosophy.” Recently, Sintetica found success in being selected in the Global Excellence Awards as the Most Innovative Pharmaceutical Company 2018, and Pasquale tells us how the team feel about this success and what it means to the firm going forwards. “It is an incredible joy first, as it represents a tangible reward to the huge efforts and strong ambition of Sintetica to move from a small Swiss excellence firm, to a leading global company. This award makes all 230 employees of Sintetica proud and honoured of the work we do. Ultimately, at the basis of this amazing international success are our values and principles.” The pharmaceutical industry is becoming increasingly competitive, in an economic and distribution sense, and Pasquale and Sintetica must work exceptionally hard to ensure the firm stays ahead of any emerging developments within the fast-paced market. Pasquale explains what techniques are used in order to increase the productivity of Sintetica, as well as what helps it to attract the best business. “Novel therapies and treatments require more and more the redevelopment of existing drugs. As such, the team enhance drug formulation, assuring the fitting of our ‘Premix’ medicines to the current standard of care. Surgical procedures can be invasive and drugs may not last as long, meaning there is an increased cost pressure on the health system which is leading to a shift towards day surgery. “Modern short and medium acting local anaesthetics are our ‘One Day Surgery’ proposal, enabling us to adapt the length and the conditions of anaesthesia to the novel surgical needs, allowing patients to go home on the same day. Furthermore, after being released, we want our patients to be able to live as normally as possible. “This means that pain has to be managed at hospital as much as possible. ‘Dual Spinal’ is our development of an innovative pain killer drug which treats the acute pain after surgery at hospital, when inducing anaesthesia. ‘Enhance Intrathecal Therapy’ is our promise as we try to improve care in the neuromodulation. As a result, we develop novel drugs and make available life-changing medicines to the largest number of patients and health care providers worldwide.” Contributing towards the overall success of Sintetica, is the working environment which provides staff with the freedom to be creative, innovative and work exceptionally hard to produce the best results. Pasquale talks about respect and the stringent hiring structure which the firm has in place, meaning it guarantees that it only hires staff who are the right fit for the firm. “The culture of total respect and the focus to the individual person shall be considered as our fundamental heritage. The people are the real stars of our business and the biggest resource we count on to grow and develop the company. “At Sintetica, we seriously take the obligation to meet the highest standards of business ethics and integrity, and make meeting those standards the responsibility of all our employees. That is why, when hiring new employees, we look for smart people who share our “...we will executive projects to improve the industrial sites which are manufacturing capacity and pharmaceutical and clinical pipeline developments that are major pillars to sustain the midterm strong growth.”